|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the M. D. Anderson Cancer Center, Houston,
TX; New York-Presbyterian Hospital Weill Medical College of Cornell
University, New York, NY; Division of Hematology, Oregon Health
Sciences University, Portland; Department of Haematology, Hammersmith
Hospital/ICSM, London, United Kingdom; Hematology Section, San Gerardo
Hospital, Monza, Italy; Department of Experimental Oncology, National
Cancer Institute, Milan, Italy; Department of Oncology Hematology and
Cell Therapy, C.H.U de Poitiers, Poitiers, France; Barbara Ann Karmanos
Cancer Institute, Wayne State University, Detroit, MI;
Universitätsklinikum, Medizinische Klinik und Poliklinik, Mainz,
Germany; Abteilung Haematologie/Onkologie, Universität Leipzig,
Leipzig, Germany; Department of Haematology, Royal Victoria Infirmary,
University of Newcastle upon Tyne, United Kingdom; Medizinische
Universitätsklinik Mannheim der Universität Heidelberg,
Mannheim, Germany; Medizinische Klinik III, Johan Wolfgang Goethe
Universität, Frankfurt, Germany; Division of Hematology,
Universitätsklinik, Kantonspital, Basel, Switzerland; Division of
Hematology, Udine University Hospital, Udine, Italy; Dana Farber Cancer
Institute, Boston, MA; Instituto di Ematologia, Ospedale Policlinicl
Sant'Orsola-Malpighi, Bologna, Italy; Laboratoire de Greffe de Moelle,
Universite Victor Segalen, Bordeaux, France; Novartis Pharma AG, Basel,
Switzerland; Department of Medicine and Molecular Biology Institute,
University of California at Los Angeles, CA.
Chronic myelogenous leukemia (CML) is caused by expression of the
BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Patients with CML in accelerated phase have
rapidly progressive disease and are characteristically unresponsive to
existing therapies. Imatinib (formerly STI571) is a rationally developed, orally administered inhibitor of the Bcr-Abl kinase. A total
of 235 CML patients were enrolled in this study, of whom 181 had a
confirmed diagnosis of accelerated phase. Patients were treated with
imatinib at 400 or 600 mg/d and were evaluated for hematologic and
cytogenetic response, time to progression, survival, and toxicity.
Imatinib induced hematologic response in 82% of patients and sustained
hematologic responses lasting at least 4 weeks in 69% (complete in
34%). The rate of major cytogenetic response was 24% (complete in
17%). Estimated 12-month progression-free and overall survival rates
were 59% and 74%, respectively. Nonhematologic toxicity was usually
mild or moderate, and hematologic toxicity was manageable. In
comparison to 400 mg, imatinib doses of 600 mg/d led to more
cytogenetic responses (28% compared to 16%), longer duration of
response (79% compared to 57% at 12 months), time to disease
progression (67% compared to 44% at 12 months), and overall survival
(78% compared to 65% at 12 months), with no clinically relevant
increase in toxicity. Orally administered imatinib is an effective and
well-tolerated treatment for patients with CML in accelerated phase. A
daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
(Blood. 2002;99:1928-1937) Accelerated phase marks the onset of advanced,
rapidly progressive chronic myelogenous leukemia (CML), a clonal
neoplastic disorder of hematopoietic stem cells.1,2 In
more than 85% of all CML patients, accelerated phase is preceded by a
prolonged chronic phase characterized by mild symptoms in most
patients.1-7 In accelerated phase, cells develop genetic
and karyotypic abnormalities leading to an increased number of poorly
differentiated cells in peripheral blood and marrow, splenomegaly, and
often to the onset of constitutional symptoms.2-8
Accelerated phase generally leads to a rapidly fatal blast crisis
within 6 months.3-8
Because accelerated phase CML is associated with numerous
hematologic, cytogenetic, and clinical signs and symptoms, no single set of criteria for its onset is universally accepted. Some groups advocate practical criteria embracing any of several events or developments that are generally associated with advanced, progressive CML. These include progressive splenomegaly; treatment-refractory thrombocytosis; rapid leukocyte doubling time; myelofibrosis; atypical
leukocytes or erythrocytes; extramedullary disease (chloromas); disease
symptoms; the presence of elevated numbers of blasts, basophils, or
eosinophils in peripheral blood or marrow; thrombocytopenia; or
karyotypic evolution.5-9 Figure
1 presents a set of criteria including
only those factors retrospectively statistically correlated with
reduced survival, comprising the presence of 15% to less than 30%
blasts, or 30% blasts and promyelocytes, or 20% basophils in
peripheral blood or marrow, or platelet counts less than
100 × 109/L unrelated to anticancer
therapy.3,4
The causative event in CML is the genetic transposition of ABL and BCR
sequences to form a BCR-ABL fusion gene, leading to the expression of a
constitutively active, fusion Bcr-Abl protein-tyrosine kinase.1,10 In at least 90% of cases, this event appears
as a t(9;22) (q34;q11) reciprocal translocation (the Philadelphia translocation), which is the most characteristic feature of
CML.10,11 Expression of the BCR-ABL gene is sufficient to
cause chronic phase CML; the progression of disease to accelerated
phase or terminal blast crisis is thought to depend on the development of additional genetic changes leading to loss of differentiation and an
increasingly aggressive clinical presentation.1,3,4,12-15
Accelerated phase CML responds poorly to therapy. The majority of
patients will have received prolonged treatment for chronic phase
disease, usually with hydroxyurea (HU) or recombinant interferon alfa
(rIFN Imatinib (Glivec [Gleevec in the United States; imatinib
mesylate; Novartis Pharma AG]) is a rationally designed, potent
selective competitive inhibitor of the Bcr-Abl protein-tyrosine
kinase.25-28 At therapeutic doses it also inhibits
tyrosine kinase activity of the platelet-derived growth factor (PDGF)
receptor Because of the observed activity and favorable tolerability of imatinib
in patients with accelerated phase CML, and because of the limited
treatment options available to these patients, we have conducted a
phase 2 trial of imatinib in patients meeting rigorous criteria for
accelerated phase CML.3,4 The study objectives were to
confirm its observed activity and favorable safety profile in a larger
patient population and to characterize prognostic factors.
Patients
Accelerated phase CML was defined by either at least 15% to less than
30% blasts in peripheral blood or marrow, or 30% or more blasts plus
promyelocytes in peripheral blood or marrow (provided that < 30%
blasts were present), or at least 20% peripheral basophils, or
thrombocytopenia defined as platelet counts of less than
100 × 109/L, unrelated to therapy.3
Patients with karyotypic evolution suggesting advanced CML but without
other evidence of accelerated phase were not eligible for enrollment.
Patients were required to have alanine aminotransferase (ALT) and
aspartate amino transferase (AST) levels not higher than 3 times the
upper normal limit in cases without suspected leukemic involvement of
the liver, or not higher than 5 times the upper normal limit in cases
of suspected liver involvement, to have serum total bilirubin levels
not higher than 3 times the upper normal limit, and serum creatinine
levels not higher than 2 times the upper normal limit. Women of
childbearing potential were required to have a negative pregnancy test
before starting treatment, and all patients were required to use
barrier contraceptive measures throughout therapy with imatinib.
Patients were excluded from the trial if they had an Eastern
Cooperative Oncology Group (ECOG) performance status of grade 3 or
higher, grade 3/4 cardiac disease, leukemic central nervous system
involvement, or any serious concomitant medical condition. Exclusion
criteria included treatment with either HU within 24 hours before
starting therapy with imatinib, or with INF All patients gave written informed consent to participate in the study,
and the study was reviewed and approved by a recognized ethics review
committee at each trial center. The study was performed in accordance
with the Declaration of Helsinki (as amended in Tokyo, Venice, and
Hong Kong).
Study design and treatment
Initially, enrolled patients received treatment with orally administered imatinib at daily doses of 400 mg. Following the availability of phase 1 dose escalation data demonstrating the safety of prolonged treatment with higher doses, this initial daily dose was increased by protocol amendment to 600 mg. For patients who had a relapse, dose escalation to a maximum of 400 mg twice daily was permitted at the discretion of the investigator. Dose escalation was also permitted for patients who did not achieve hematologic response after at least 1 month of therapy, on a case-by-case basis following discussion between the investigator and sponsor. Patients received treatment for 24 weeks, and then treatment was continued indefinitely in cases where the investigator judged that further treatment was of clinical benefit. Treatment was interrupted or reduced in response to nonhematologic, hepatic, or hematologic toxicity, which was graded according to National Cancer Institute/National Institutes of Health (NCI/NIH) Common Toxicity Criteria (CTC). For patients requiring dose reduction, daily doses were reduced from 600 to 400 mg or from 400 to 300 mg. Dose reduction below 300 mg/d was discouraged in light of recent pharmacokinetic analyses indicating that treatment with imatinib at 200 mg/d results in subtherapeutic drug levels in a fraction of patients.41 If grade 2 nonhematologic toxicity occurred, therapy was interrupted until recovery to grade 1 or less, and resumed at the original dosage. If grade 2 toxicity recurred following resumption, treatment was again interrupted until recovery, and resumed at a reduced dose. If grade 3 or 4 nonhematologic toxicity occurred, therapy was interrupted until recovery to grade 2 or less, and resumed at a reduced dose. Specific dose reduction rules for hepatic toxicity were applied to patients who enrolled with elevated baseline transaminase levels (3-fold to 5-fold above upper normal limits). If such patients developed increases of more than 3-fold in one or more transaminase levels, therapy was interrupted until levels returned to baseline, and resumed at a reduced dose. For patients who experienced clinically relevant, but less than 3-fold increases in transaminase levels, treatment was interrupted until recovery, and resumed at the same dose. If patients experienced a subsequent clinically relevant increase in transaminase levels, treatment was interrupted until recovery, and resumed at a reduced dose. Dose reductions for hematologic toxicity were only to be considered for patients with grade 4 neutropenia (neutrophil count < 0.5 × 109/L) lasting at least 2 weeks, after a minimum of 28 days of therapy. In practice, however, imatinib doses were also reduced in cases of grade 4 thrombocytopenia considered to be unrelated to leukemia. Bone marrow examinations were performed routinely, and biopsies obtained in so far as possible, until recovery from grade 4 neutropenia or thrombocytopenia. For patients with persistent marrow cellularity less than 10% and blasts less than 10%, the daily dosage was successively reduced at 2-week intervals or was interrupted until recovery of neutropenia or thrombocytopenia to grade 2 or better. On recovery, treatment was resumed at the full initial dose. Treatment was not interrupted or reduced for patients with marrow cellularity or blasts more than 10%. No concomitant anticancer drugs were administered, with the exception of HU, anagrelide, or leukopheresis, all 3 being permitted during the first 28 days of study treatment. Within the first 28 days of treatment, HU could be given at a maximum dose of 5 g/d for up to a total of 7 days if required to control elevated blast or platelet counts. Leukopheresis was allowed up to a maximum of 2 procedures per week or 4 procedures during the first 28 days. Treatment with allopurinol at 300 mg/d was recommended until stabilization of white blood cell (WBC) counts, and patients with febrile neutropenia or infection could receive treatment with colony-stimulating factors at the investigator's discretion. Evaluation of patients Patients were evaluated for hematologic and cytogenetic response and relapse at frequent intervals during the initial 24 weeks of imatinib treatment. Peripheral blood samples were obtained and analyzed at baseline, 3 times weekly for the first 4 weeks, weekly between weeks 5 and 13, every 2 weeks after week 13, and on the last day of treatment. Bone marrow aspirates were performed at screening, at weeks 5, 9, 13, and 25, and on the last day of treatment; bone marrow biopsies were optional and obtained as indicated. Physical examination to evaluate liver and spleen size and extramedullary involvement was carried out at screening, every 4 weeks during therapy, and on the last day of treatment. After the initial 24 weeks of treatment, bone marrow aspirates or biopsies for analysis of disease status were obtained every 3 months for the first 6 months, and every 4 months thereafter. Following treatment, patients were followed for survival at least every 3 months, until death. Treatment toxicity was evaluated by patient interview at each office visit. Toxicity was graded according to the NCI/NIH CTC.31The primary efficacy end point in this study was sustained hematologic response lasting at least 4 weeks, assessed by the investigator as (1) complete hematologic response (CHR); (2) marrow response; or (3) return of chronic phase. CHR was defined according to conventional criteria as myeloblast count less than 5% in bone marrow, with no myeloblasts in peripheral blood, neutrophil count at least 1.5 × 109/L and platelet count at least 100 × 109/L, and no evidence of extramedullary involvement. In patients not achieving a CHR, marrow response was defined as myeloblast count less than 5% in bone marrow, with no myeloblasts in peripheral blood, neutrophil count at least 1.0 × 109/L, and platelet count at least 20 × 109/L (without platelet transfusion and without evidence of bleeding), and no evidence of extramedullary involvement. A return of chronic phase was defined as less than 15% myeloblasts in peripheral blood and bone marrow, with less than 30% myeloblasts plus promyelocytes in the peripheral blood and bone marrow, less than 20% peripheral basophils, and no extramedullary involvement other than in liver or spleen. Sustained responses were required to be observed at 2 consecutive evaluations at least 4 weeks apart. Secondary efficacy end points were the induction of cytogenetic response, duration of hematologic response, time to disease progression, and overall survival. Cytogenetic response was based on the prevalence of Ph+ metaphases among at least 20 metaphase cells in each bone marrow sample and was defined as complete (0% Ph+ cells), partial (1%-35%), minor (36%-65%), minimal (66%-95%), none (> 95%). Major cytogenetic response was defined as either a complete or partial response. Duration of hematologic or major cytogenetic response was calculated for all responders as the time from the first reported date of response to the earliest date of reported relapse or death. Duration of response was censored at last examination date for patients with ongoing response or patients who discontinued treatment for reasons other than adverse events, progression, or death. A single determination not fulfilling the criteria for "return to chronic phase" was considered a relapse. Time to disease progression was calculated for all patients as the time from treatment start to the onset date of blast crisis, relapse (for responding patients), discontinuation of therapy, or death from any cause. This time was censored at last examination date for patients without progression or patients who discontinued treatment for reasons other than adverse events, progression, or death. Overall survival was calculated as the time from treatment start to the date of death from any cause. Survival was censored at the time treatment was discontinued to allow BMT, or at the last recorded contact or evaluation when patients were alive at time of analysis. Statistical analysis This study was designed to demonstrate whether the overall hematologic response rate (CHR, marrow response, or return to chronic phase) was at least 30% in patients with CML in accelerated phase. A required sample size of 68 evaluable patients was based on the Fleming single-stage procedure, testing H0: P 30%
and H1: P  50%, with alpha = 2.5%
(one-sided), and power of 90%. To allow for premature withdrawals, the
planned sample size consisted of 100 patients with CML in
accelerated phase.
Efficacy results are presented for all patients with a confirmed diagnosis of CML in accelerated phase and for all enrolled patients. Response rates are reported as intent-to-treat analyses. Patients who withdrew from treatment before a sustained response was reported were counted as nonresponders. Response duration, time to progression, and survival were computed using standard Kaplan-Meier methods. Safety results are reported for all enrolled patients who received at least one dose of imatinib. Univariate and multivariate analyses were performed to test for effects
of potential prognostic factors on the hematologic response rate, time
to disease progression, and overall survival. The
Patients and treatment A total of 235 patients were enrolled at 18 centers in France (2 centers), Germany (4 center), Italy (3 centers), Switzerland (1 center), the United Kingdom (2 center), and the United States (6 centers) from August 1999 to March 2000; efficacy and safety data for analysis were collected through January 2001. Patient enrollment was allowed to exceed the original planned accrual as follow-up data from an earlier phase 1 study became available and provided increasing evidence of the activity and safety of imatinib in patients with CML in advanced phases.30 Patients were diagnosed with Ph+ or BCR-ABL+ CML in accelerated phase during the screening period for patient selection. Based on a central review of data from screening and baseline tests, 181 (77%) patients had a confirmed diagnosis of CML with protocol-specified features of accelerated phase3 at the start of imatinib therapy, whereas this disease stage could not be confirmed at treatment start for 54 (23%) enrolled patients. For these 54 patients, disease features at screening, or developing between screening and treatment start, were consistent with chronic phase CML (16 patients), blast crisis (29 patients), or the disease phase could not be determined from available information (9 patients).Table 1 presents a summary of patient
disease history and baseline characteristics. Among the 235 enrolled
patients and the 181 patients with confirmed diagnoses of accelerated
phase CML, respectively, 77 (33%) and 62 (34%) started their initial
therapy with imatinib at daily doses of 400 mg, whereas the initial
daily dose was 600 mg for the remaining 158 (67%) and 119 (66%)
patients. As shown in Table 1, patients in both dose groups had similar hematologic and cytogenetic characteristics. Among patients with confirmed diagnoses, accelerated phase was newly diagnosed in 62 patients (34%), whereas 119 patients (66%) had received prior therapy
for CML in accelerated phase, most often with HU (101 patients),
rIFN
At the time of data analysis, median treatment durations were 10 months (range, 0.2-17 months) for the 77 patients in the 400-mg dose group and 11 months (range, 0.2-15 months) for the 158 patients in 600-mg dose groups, and median actual dose intensities were 400 mg/d and 578 mg/d, respectively. Of the 235 patients enrolled, 100 (43%) patients were withdrawn from treatment. Reasons for withdrawal in the 400-mg and 600-mg dose groups, respectively, were disease progression or unsatisfactory therapeutic effect for 36 (47%) and 37 (23%) patients, adverse events for 2 (3%) and 12 (8%) patients, death during therapy for 6 (8%) and 1 (0.6%) patients, initiation of BMT therapy for 3 (4%) and 1 (0.6%) patients, or withdrawal of consent for 0 and 2 (1%) patients. Efficacy Efficacy analyses were based on the 181 patients with confirmed diagnoses of CML in accelerated phase. Table 2 presents a summary of hematologic response rates for patients with confirmed diagnoses and for those in each initial dose group. Values represent the best response observed at any time during therapy. Of the 181 patients, 82% had reductions in blast counts in peripheral blood and in bone marrow corresponding to hematologic response on at least one occasion. Sustained hematologic responses lasting at least 4 weeks were reported for 69% of patients, including 34% CHR, with similar response rates for patients in the 400-mg and 600-mg dose groups. As shown in Figure 2, the median time to hematologic response was 1 month in both groups, corresponding to the first scheduled evaluation of hematologic response, and response was usually achieved within 3 months after starting therapy.
Most hematologic responses were induced at the initially assigned dose level, and the effects of imatinib dose escalation were not systematically studied. However, dose escalation (to a maximum daily dose of 800 mg) led to hematologic responses in 4 patients (of which one was a sustained response lasting at least 4 weeks) who had not responded to initial therapy. Figure 3 depicts the duration of
hematologic response for patients in each dose group with confirmed
diagnoses of accelerated phase. Only patients with a response lasting
at least 4 weeks were included in this analysis. The estimated median
response duration was 13.4 months for patients in the 400-mg dose
group; it had not been reached at the time of analysis for patients in the 600-mg dose group. Estimated response duration exceeded 12 months
for 57% of patients in the 400-mg dose group (95% CI, 40%-73%), for
79% of patients in the 600-mg dose group (95% CI, 69%-88%), and for
70% of the 181 patients in either dose group (95% CI, 61%-80%).
As shown in Table 3, major cytogenetic
responses were reported for 43 (24%) patients, and major, minor, or
minimal cytogenetic response was reported for 86 (48%) patients. The
median time to major cytogenetic response was similar for patients in
the 400-mg dose group (2.4 months) and the 600-mg group (2.9 months),
and mostly corresponded to the first evaluation of cytogenetic
response. However, major cytogenetic responses were achieved up to 12 months after starting therapy. Cytogenetic response was only evaluated every 3 months, and therefore the duration of response cannot be
calculated with precision. Among patients with major cytogenetic responses, the estimated duration of response was at least 9 months in
42% of patients in the 400-mg dose group (95% CI, 8%-76%), in 71%
of patients in the 600-mg dose group (95% CI, 54%-88%), and in 64%
of patients overall (95% CI, 48%-80%).
Figure 4 depicts time to disease
progression (onset of blast crisis or loss of hematologic response) for
patients in each dose group with confirmed diagnoses of accelerated
phase. The median time to progression was 8.8 months for patients in
the 400-mg dose group, and had not been reached at the time of analysis for patients in the 600-mg dose group. Estimated time to progression exceeded 12 months in 44% of patients in the 400-mg dosing group (95%
CI, 31%-56%), in 67% of patients in the 600-mg dosing group (95%
CI, 59%-76%), and in 59% of the 181 patients in either dosing group
(85% CI, 52%-66%).
Figure 5 depicts overall survival for
patients in the 400-mg and 600-mg dose groups with a confirmed
diagnosis of CML in accelerated phase. At the time of analysis, median
survival had not been reached for patients in either dosing group.
Estimated overall survival rates at 12 months were 65% for patients in
the 400-mg dose group (95% CI, 53%-77%), 78% for patients in the
600-mg dose group (95% CI, 70%-87%), and 74% for all 181 patients
(95% CI, 68%-81%). Notably, all patients who achieved a major
cytogenetic response within 3 months of therapy were alive at the time
of analysis, regardless of their initial imatinib
dose (Figure 6).
Univariate analyses and regression models were applied to test for the
effects of several baseline variables on time to disease progression.
Table 4 lists the prognostic variables
included in these analyses, the cutoff values used to define patient
subgroups, and the results. Data for 2 variables (blasts in bone marrow
and additional chromosomal abnormalities) were unavailable in a
substantial number of patients, and for this reason 2 separate analyses
were performed, one excluding these factors but including all patients with confirmed diagnosis, and secondary analyses to evaluate the additional effects of these 2 factors separately, limited to the subset
of patients with data for all variables.
In multivariate analysis, the factors most strongly predictive of longer time to disease progression were hemoglobin at least 100 g/L, and a starting dose of 600 mg imatinib. Female sex was marginally predictive in this analysis. In subgroup analyses excluding patients without data for blasts in bone marrow or additional chromosomal abnormalities, neither variable added further to the prediction of hematologic response in multivariate analyses (P > .10). Further analyses indicated that varying the cutoff values used to define patient subgroups had little effect on most prognostic factors. Platelet counts of less than 40 × 109/L were independently predictive of shorter time to disease progression in exploratory analyses, but the reliability of this result was limited by the small number of patients in this subgroup. The use of different cutoff values for hemoglobin (< 110 g/L) and blasts in peripheral blood (< 5%) led to the elimination of male/female sex as a marginal prognostic factor in the final multivariate model, and to the inclusion of high platelet counts and low blast counts in peripheral blood as predictive of longer time to disease progression. In further exploratory multivariate analyses, a hemoglobin value of 100 g/L or higher was the sole factor significantly predictive for higher rates of sustained hematologic response. Exploratory multivariate analyses of prognostic factors for overall survival were limited by the small number of patients who had died, but results identified 4 factors as predictive of longer survival: a starting dose of 600 mg imatinib, WBC count less than 30 × 109/L, platelets at least 100 × 109/L, and absence of splenomegaly. Efficacy results for all 235 enrolled patients were similar in all respects to those for the 181 patients with confirmed diagnoses of accelerated phase. For the 235 enrolled patients, the overall rate of hematologic response lasting at least 4 weeks was 68%, including 35% CHR. The rate of major cytogenetic response was 23%, with 17% complete cytogenetic responses. The estimated duration of hematologic response exceeded 12 months in 71% of patients. Estimated time to disease progression exceeded 12 months in 60% of patients, and estimated overall survival exceeded 12 months in 75% of patients. Prognostic factors identified for the 181 patients with confirmed diagnosis (Table 4) were similar for all 235 enrolled patients. Toxicity The toxicity of imatinib in this trial was generally similar to that observed in a previous phase 1 study at comparable doses. Table 5 presents treatment-related adverse events observed in 5% of patients or more. The most frequently reported events were nausea, edema, vomiting, diarrhea, and muscle cramps. Grade 1 or 2 edema, dermatitis, vomiting, muscle cramps, myalgia, arthralgia, and weight increase/fluid retention were generally more frequent in the 600-mg dose group than for patients treated with imatinib at 400 mg/d, but the incidences of other grade 1 or 2 reactions, and of all grade 3 and 4 reactions, were similar in both dose groups. Routine laboratory tests revealed infrequent development of grade 3 abnormalities in AST (2% of patients), in ALT (3%), and bilirubin (2%) during treatment.
Table 6 presents the numbers of
patients who developed grade 3 or 4 hematologic abnormalities during
treatment with imatinib. Frequencies were comparable in the 400-mg and
600-mg groups for all grade 3 or 4 abnormalities, and in both groups
the most commonly reported abnormality was neutropenia. Median times
from treatment start to nadir were 74 days for neutropenia and 57 days
for thrombocytopenia. Among patients who developed grade 3 or 4 abnormalities, median times to recovery to grade 2 values or better
were 21 days for neutropenia and 30 days for thrombocytopenia.
Adverse events, whether related or unrelated to treatment, led to dose reductions on one or more occasions in 38 (49%) patients in the 400-mg dose group and in 82 (52%) patients in the 600-mg dose group. Adverse events related to treatment led to the discontinuation of imatinib therapy in 6 patients, all in the 600-mg dose group, and comprised skin rash (2 patients), thrombocytopenia (1 patient), hepatobiliary disorders (Budd-Chiari syndrome and hepatotoxicity in 1 patient each), and gastric ulcer hemorrhage (1 patient). Treatment-related adverse events regarded as serious were reported for 8 (10.4%) patients in the 400-mg dose group and 24 (15.2%) patients in the 600-mg dose group, and most frequently comprised cytopenia or gastrointestinal events. One death due to liver failure was suspected to be related to therapy. This patient had undergone prior BMT and had received daily doses of 3000 to 3500 mg acetaminophen for approximately 1 month before starting treatment with imatinib at 600 mg/d. After 6 days of treatment the patient developed upper quadrant discomfort and jaundice, laboratory tests revealed markedly elevated bilirubin and transaminases, and imatinib therapy was stopped on day 7. Tests for infection were negative. The patient's condition deteriorated from day 10 and death occurred on day 12.
We conducted this phase 2 study to determine whether imatinib, a potent inhibitor of the oncogenic Bcr-Abl tyrosine kinase, could induce hematologic responses in at least 30% of patients with CML in accelerated phase, when administered at well-tolerated doses defined in earlier trials.28-30 Results indicate that imatinib induced hematologic response lasting at least 4 weeks in 69% of patients, including CHR in 34% of patients, with manageable hematologic toxicity and few nonhematologic grade 3 or 4 adverse reactions. Treatment with imatinib also induced major cytogenetic responses in 24% of patients, 12-month progression-free survival in 59% of patients, and 12-month overall survival in 74% of patients. The efficacy of imatinib in this study far exceeded the planned success criteria defined in the protocol. The demographic features, disease history and baseline characteristics, and major prognostic factors of the patients enrolled in this trial appear to be consistent with those described in other studies with similar patients.3,5-9 Notably, the criteria3,4 used to define accelerated phase in this trial are more stringent than those of the International Bone Marrow Transplant Registry (IBMTR)7 or Sokal8 classification systems, and patients with cytogenetic clonal evolution as a sole criterion for accelerated phase, representing a heterogeneous group with generally favorable prognosis,32,33 were excluded from this trial. Accordingly, the positive results observed with imatinib in this study are unlikely to be attributable to the selection of patients with favorable prognosis. The analysis of prognostic factors for response, time to progression, and survival must be interpreted with caution because of the high correlation between many of the factors included in the model and the limited follow-up at the time of analysis. Although the effects of prognostic factors were not completely consistent across all 3 end points, an initial dose of 600 mg imatinib and absence of baseline anemia were found to be strongly predictive of favorable outcome. Although this trial was not designed as a randomized dose-finding study, the identification of a high starting dose of imatinib as a positive prognostic factor, and inspection of efficacy results in general, suggest that disease control is more durable when imatinib therapy is initiated and maintained at 600 mg/d rather than 400 mg/d. Hematologic response duration, cytogenetic response rates, progression-free survival, and overall survival were consistently better for patients who started imatinib therapy at 600 mg/d, although hematologic response rates did not differ greatly between dosage groups. These groups of patients had similar disease characteristics and histories, indicating that outcomes were unlikely to be influenced by differences in prognosis (Table 1). Because the toxicity of imatinib at 600 mg/d is manageable, overall results of this trial support the conclusion that patients with accelerated phase CML derive greater benefit from imatinib therapy at 600 mg/d than with 400 mg/d. Dose escalation above 600 mg/d was not systematically studied, but an increase in the initial dose to a maximum of 800 mg/d led to the induction of sustained or transient hematologic responses in a small number of cases. A comparison of the results of this study with historical reports
suggests that imatinib may bring substantially increased efficacy to
the treatment of patients in CML accelerated phase, compared to current
alternative biologic agents or chemotherapies. Among patients in the
600-mg dose group, overall and complete hematologic response rates of
71% and 37%, respectively, compare favorably with the range of
approximately 20% to 60% overall response in similar patients treated
with single agent therapies,16-18 rIFN Despite treatment-related mortality rates of approximately 50%, allogeneic stem cell transplantation is potentially curative, even in patients with advanced CML. Disease-free survival rates ranging from 20% to 40% at 4 years have been reported for patients meeting various definitions of CML in accelerated phase.19-24 Because allogeneic transplantation is more often successful in patients with early rather than advanced CML,25 clinical trials may be warranted to test whether preparative induction of response with imatinib improves the outcome of subsequent transplantation. Although imatinib showed remarkable clinical activity in this group of patients, a substantial fraction of them ultimately had a relapse with resistant disease. Mechanisms of in vivo resistance to imatinib do not appear to involve drug absorption or metabolism.30 Resistance in many patients has been due to point mutations in the BCR-ABL oncogene.36 Other plausible resistance mechanisms obtained from in vitro models are postulated to involve amplification of the BCR-ABL fusion gene, drug efflux, increased expression of the Bcr-Abl protein, or decreased cellular bioavailability of imatinib.37-40 Because imatinib is well tolerated, it may be feasible to combine imatinib with existing agents used to treat CML in accelerated phase. Accordingly, further clinical trials are warranted to test the optimal use of imatinib in combination with other active agents.
We wish to thank the numerous coinvestigators, nursing staff, and clinical trial monitors who participated in this study. The contributions of data managers and programmers at Novartis Pharmaceuticals are gratefully acknowledged. Dr David Parkinson and Dr Greg Burke provided invaluable support, and we thank Dr John Ford, Dr Elisabeth Wehrle, and Dr Marianne Rosamilia for their collaboration in implementing the protocol and reporting the study results, and Dr Thomas Brown for assistance in preparing the manuscript.
Submitted June 11, 2001; accepted October 18, 2001.
Supported by a grant from Novartis Pharmaceuticals AG, Basel, Switzerland. This study was presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1-5, 2000, San Francisco, CA.
Three authors (S.F.-R., I.G., and R.C.) are employees of Novartis Pharma AG.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: M. Talpaz, M.D. Anderson Cancer Center, Houston, TX; e-mail: mtalpaz{at}mail.mdanderson.org.
1.
Sawyers CL.
Chronic myeloid leukemia.
N Engl J Med.
1999;340:1330-1340
2.
Faderl S, Talpaz M, Estrov Z, et al.
Chronic myelogenous leukemia: biology and therapy.
Ann Intern Med.
1999;131:207-219 3. Kantarjian HM, Dixon D, Keating M, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446[CrossRef][Medline] [Order article via Infotrieve].
4.
Kantarjian HM, Deisseroth A, Kurzrock R, et al.
Chronic myelogenous leukemia: a concise update.
Blood.
1993;82:691-703
5.
Karanas A, Silver RT.
Characteristics of the terminal phase of chronic granulocytic leukemia.
Blood.
1968;32:445-459 6. Arlin ZA, Silver RT, Bennet JM. Blastic phase of chronic myeloid leukemia (blVML): a proposal for standardization of diagnostic and response criteria. Leukemia. 1990;4:756-757. 7. Speck B, Bortin MM, Champlin R, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia. Lancet. 1984;1:665-668[Medline] [Order article via Infotrieve]. 8. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61[Medline] [Order article via Infotrieve].
9.
Kantarjian HM, O'Brien S, Anderlini P, et al.
Treatment of chronic myelogenous leukemia: current status and investigational options.
Blood.
1996;87:3069-3081 10. Rowley D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;43:290-293. 11. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497-1501. 12. Heisterkamp N, Jenster G, ten Hoeve J, et al. Acute leukemia in bcr/abl transgenic mice. Nature. 1990;344:251-253[CrossRef][Medline] [Order article via Infotrieve].
13.
Daley GQ, Van Etten RA, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830
14.
Kelliher MA, McLaughlin J, Witte ON, et al.
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Proc Natl Acad Sci U S A.
1990;87:6649-6653 15. Elefanty AG, Hariharan IK, Cory S. Bcr/abl, the hallmark of chronic myelogenous leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078[Medline] [Order article via Infotrieve].
16.
Silver RT, Woolf SH, Hehlmann R, et al.
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemias: developed for the American Society of Hematology.
Blood.
1999;94:1517-1536 17. Enright H, McGlave P. Chronic myelogenous leukemia. In: Hoffman R,Benz EJ,Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1155-1171.
18.
Kantarjian H, Talpaz M, Kontayiannis D, et al.
Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine and granulocyte macrophage colony stimulating factor.
J Clin Oncol.
1992;10:398-405 19. Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol. 1997;99:30-35[CrossRef][Medline] [Order article via Infotrieve]. 20. Gratwohl A, Hermans J, Niederwieser D, et al. for the Chronic Myeloid Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone marrow transplantation for chronic myeloid leukemia: long term results. Bone Marrow Transplant. 1993;12:509-516[Medline] [Order article via Infotrieve]. 21. McGlave P. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia. 1992;6(suppl.):115-117.
22.
Clift RA, Buckner CD, Thomas ED, et al.
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia.
Blood.
1994;84:4368-4373 23. Reiter E, Greinix HT, Keil F, et al. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol. 1999;78:507-513[CrossRef][Medline] [Order article via Infotrieve]. 24. Enright H, Daniels K, Arthur DC, et al. Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant. 1996;17:537-542[Medline] [Order article via Infotrieve]. 25. Druker BJ, Tamura S. Buchdunger E, et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med. 1996;2:561-566[CrossRef][Medline] [Order article via Infotrieve].
26.
Deininger MW, Goldman JM, Lydon N, et al.
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood.
1997;90:3691-3698 27. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemia cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394[CrossRef][Medline] [Order article via Infotrieve]. 28. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7[Medline] [Order article via Infotrieve].
29.
Druker BJ, Talpaz M, Resta DJ, et al.
Clinical efficacy and safety of an abl specific tyrosine kinase inhibitor as targeted therapy for chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037
30.
Druker BJ, Sawyers CL, Kantarjian H, et al.
Activity of an abl specific tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis and other Philadelphia chromosome positive acute leukemias.
N Engl J Med.
2001;344:1038-1042 31. Cancer Therapy Evaluation Program. Common Toxicity Criteria Version 2.0. CDTD, NCI, NIH, DHSS. March 1998. [http://ctep.info.nih.gov/ctc3.htm]. 32. Majlis A, Smith T, Talpaz M, et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996;14:196-203[Abstract].
33.
Kantarjian HM, Keating M, Estey EH, et al.
Treatment of advanced stages of Philadelphia chromosome positive chronic myelogenous leukemia with interferon-alpha and low dose cytarabine.
J Clin Oncol.
1992;10:772-778
34.
Kantarjian HM, Talpaz M, Smith TL, et al.
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
J Clin Oncol.
2000;18:3513-3521
35.
Coleman MC, Silver RT, Pajak TF, et al.
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: Cancer and Leukemia Group B studies.
Blood.
1980;55:29-36 36. Marx J. Cancer research: why some leukemia cells resist STI-571. Science. 2001;292:2231-2233.
37.
le Coutre P, Tassi E, Varella-Garcia M, et al.
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
Blood.
2000;95:1758-1766
38.
Weisberg E, Griffin JD.
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cells.
Blood.
2000;95:3498-3505
39.
Mahon FX, Deininger MWN, Schultheis B, et al.
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance.
Blood.
2000;96:1070-1079
40.
Gambacorti-Passerini C, Barni R, le Coutre P, et al.
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
J Natl Cancer Inst.
2000;92:1641-1650 41. Peng B, Hayes M, Racine-Poon A, et al. Clinical investigation of the PK/PD relationship for Glivec (STI571): a novel inhibitor of signal transduction. American Society of Clinical Oncology 37th meeting; May 12-15, 2001; San Francisco, CA. Abstract 280.
In addition to the authors, the following investigators participated in this trial: M. Schuster, New York, NY; M. O'Dwyer, Portland, OR; J. F. Apperly, London, United Kingdom; G. Corneo, Milan, Italy; C. Karanes, Detroit, MI; J. Beck, Mainz, Germany; H.-K. Al-Ali, Leipzig, Germany; S. G. O'Brien, Newcastle upon Tyne, United Kingdom; R. Hehlmann, Mannheim, Germany; B. Wassmann, Frankfurt, Germany; D. Heim, Basel, Switzerland; D. Russo, Udine, Italy; D. Deangelo, Boston, MA; G. Rosti, Bologna, Italy; and R. Paquette, Los Angeles, CA.
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. E. Cortes, H. M. Kantarjian, S. L. Goldberg, B. L. Powell, F. J. Giles, M. Wetzler, L. Akard, J. M. Burke, R. Kerr, M. Saleh, et al. High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses J. Clin. Oncol., October 1, 2009; 27(28): 4754 - 4759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Verma, H. M. Kantarjian, D. Jones, R. Luthra, G. Borthakur, S. Verstovsek, M. B. Rios, and J. Cortes Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance Blood, September 10, 2009; 114(11): 2232 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Apperley, J. E. Cortes, D.-W. Kim, L. Roy, G. J. Roboz, G. Rosti, E. O. Bullorsky, E. Abruzzese, A. Hochhaus, D. Heim, et al. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial J. Clin. Oncol., July 20, 2009; 27(21): 3472 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kantarjian, J. Cortes, D.-W. Kim, P. Dorlhiac-Llacer, R. Pasquini, J. DiPersio, M. C. Muller, J. P. Radich, H. J. Khoury, N. Khoroshko, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up Blood, June 18, 2009; 113(25): 6322 - 6329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Noens, M.-A. van Lierde, R. De Bock, G. Verhoef, P. Zachee, Z. Berneman, P. Martiat, P. Mineur, K. Van Eygen, K. MacDonald, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study Blood, May 28, 2009; 113(22): 5401 - 5411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study Blood, May 7, 2009; 113(19): 4497 - 4504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Silver, J. Cortes, R. Waltzman, M. Mone, and H. Kantarjian Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials Haematologica, May 1, 2009; 94(5): 743 - 744. [Full Text] [PDF]
|
|
|
|
|
|
F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party Blood, April 9, 2009; 113(15): 3428 - 3434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Barros Costa Review Article: Targeted Therapy: Comprehensive Review American Journal of Hospice and Palliative Medicine, April 1, 2009; 26(2): 137 - 146. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Lagas, R. A.B. van Waterschoot, V. A.C.J. van Tilburg, M. J. Hillebrand, N. Lankheet, H. Rosing, J. H. Beijnen, and A. H. Schinkel Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment Clin. Cancer Res., April 1, 2009; 15(7): 2344 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, D. Jones, J. Shan, S. O'Brien, N. Reddy, W. G. Wierda, S. Faderl, G. Garcia-Manero, S. Verstovsek, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy Blood, March 5, 2009; 113(10): 2154 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-F. Wong Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 17 - 27. [Abstract] [PDF]
|
|
|
|
|
|
F. Palandri, F. Castagnetti, G. Alimena, N. Testoni, M. Breccia, S. Luatti, G. Rege-Cambrin, F. Stagno, G. Specchia, B. Martino, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up Haematologica, February 1, 2009; 94(2): 205 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood, December 15, 2008; 112(13): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy Blood, November 15, 2008; 112(10): 3965 - 3973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Okabe, T. Tauchi, and K. Ohyashiki Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells Clin. Cancer Res., October 1, 2008; 14(19): 6181 - 6186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Capdeville, T. Krahnke, A. Hatfield, J. M. Ford, I. Van Hoomissen, and I. Gathmann Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias Ann. Onc., July 1, 2008; 19(7): 1320 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Deininger Nilotinib Clin. Cancer Res., July 1, 2008; 14(13): 4027 - 4031. [Full Text] [PDF]
|
|
|
|
|
|
F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome Haematologica, May 1, 2008; 93(5): 770 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gontarewicz, S. Balabanov, G. Keller, R. Colombo, A. Graziano, E. Pesenti, D. Benten, C. Bokemeyer, W. Fiedler, J. Moll, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I Blood, April 15, 2008; 111(8): 4355 - 4364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. O'Hare, C. A. Eide, J. W. Tyner, A. S. Corbin, M. J. Wong, S. Buchanan, K. Holme, K. A. Jessen, C. Tang, H. A. Lewis, et al. SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib PNAS, April 8, 2008; 105(14): 5507 - 5512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Kenealy, C. B. Christenson, and C. B. Williams Current Therapies for Chronic Myeloid Leukemia Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Ramirez and J. F. DiPersio Therapy Options in Imatinib Failures Oncologist, April 1, 2008; 13(4): 424 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia Blood, March 1, 2008; 111(5): 2854 - 2865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. le Coutre, O. G. Ottmann, F. Giles, D.-W. Kim, J. Cortes, N. Gattermann, J. F. Apperley, R. A. Larson, E. Abruzzese, S. G. O'Brien, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia Blood, February 15, 2008; 111(4): 1834 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF]
|
|
|
|
|
|
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment Blood, February 1, 2008; 111(3): 1039 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Palandri, I. Iacobucci, G. Martinelli, M. Amabile, A. Poerio, N. Testoni, S. Soverini, F. Castagnetti, A. De Vivo, M. Breccia, et al. Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML J. Clin. Oncol., January 1, 2008; 26(1): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fausel Targeted chronic myeloid leukemia therapy: Seeking a cure Am. J. Health Syst. Pharm., December 15, 2007; 64(24_Supplement_15): S9 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Agis, W. R. Sperr, S. Herndlhofer, H. Semper, H. Pirc-Danoewinata, O. A. Haas, C. Mannhalter, H. Esterbauer, K. Geissler, C. Sillaber, et al. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571) Ann. Onc., November 1, 2007; 18(11): 1834 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. White, V. Saunders, A. Grigg, C. Arthur, R. Filshie, M. F. Leahy, K. Lynch, L. B. To, and T. Hughes Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia J. Clin. Oncol., October 1, 2007; 25(28): 4445 - 4451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Atallah, J.-B. Durand, H. Kantarjian, and J. Cortes Congestive heart failure is a rare event in patients receiving imatinib therapy Blood, August 15, 2007; 110(4): 1233 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Schiffer BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia N. Engl. J. Med., July 19, 2007; 357(3): 258 - 265. [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Y. Kuo and Z.-F. Chang GATA-1 and Gfi-1B Interplay To Regulate Bcl-xL Transcription Mol. Cell. Biol., June 15, 2007; 27(12): 4261 - 4272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guilhot, J. Apperley, D.-W. Kim, E. O. Bullorsky, M. Baccarani, G. J. Roboz, S. Amadori, C. A. de Souza, J. H. Lipton, A. Hochhaus, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase Blood, May 15, 2007; 109(10): 4143 - 4150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, P. Rousselot, D.-W. Kim, E. Ritchie, N. Hamerschlak, S. Coutre, A. Hochhaus, F. Guilhot, G. Saglio, J. Apperley, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Blood, April 15, 2007; 109(8): 3207 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, A. Quintas-Cardama, and J. Cortes Important Therapeutic Targets in Chronic Myelogenous Leukemia Clin. Cancer Res., February 15, 2007; 13(4): 1089 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Balabanov, A. Gontarewicz, P. Ziegler, U. Hartmann, W. Kammer, M. Copland, U. Brassat, M. Priemer, I. Hauber, T. Wilhelm, et al. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach Blood, February 15, 2007; 109(4): 1701 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Oehler, T. Gooley, D. S. Snyder, L. Johnston, A. Lin, C. C. Cummings, S. Chu, R. Bhatia, S. J. Forman, R. S. Negrin, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood, February 15, 2007; 109(4): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Holtz, S. J. Forman, and R. Bhatia Growth Factor Stimulation Reduces Residual Quiescent Chronic Myelogenous Leukemia Progenitors Remaining after Imatinib Treatment Cancer Res., February 1, 2007; 67(3): 1113 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rosti, I. Iacobucci, S. Bassi, F. Castagnetti, M. Amabile, D. Cilloni, A. Poerio, S. Soverini, F. Palandri, G. R. Cambrin, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party Haematologica, January 1, 2007; 92(1): 101 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Kantarjian, M. Talpaz, F. Giles, S. O'Brien, and J. Cortes New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance Ann Intern Med, December 19, 2006; 145(12): 913 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Soverini, S. Colarossi, A. Gnani, G. Rosti, F. Castagnetti, A. Poerio, I. Iacobucci, M. Amabile, E. Abruzzese, E. Orlandi, et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2006; 12(24): 7374 - 7379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Druker, F. Guilhot, S. G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. W.N. Deininger, R. T. Silver, J. M. Goldman, R. M. Stone, et al. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia N. Engl. J. Med., December 7, 2006; 355(23): 2408 - 2417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure Clin. Cancer Res., December 1, 2006; 12(23): 7180 - 7186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Puttini, A. M. L. Coluccia, F. Boschelli, L. Cleris, E. Marchesi, A. Donella-Deana, S. Ahmed, S. Redaelli, R. Piazza, V. Magistroni, et al. In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells Cancer Res., December 1, 2006; 66(23): 11314 - 11322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. DeAngelo, R. M. Stone, M. L. Heaney, S. D. Nimer, R. L. Paquette, R. B. Klisovic, M. A. Caligiuri, M. R. Cooper, J.-M. Lecerf, M. D. Karol, et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics Blood, December 1, 2006; 108(12): 3674 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Bradeen, C. A. Eide, T. O'Hare, K. J. Johnson, S. G. Willis, F. Y. Lee, B. J. Druker, and M. W. Deininger Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations Blood, October 1, 2006; 108(7): 2332 - 2338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jabbour, J. Cortes, H. M. Kantarjian, S. Giralt, D. Jones, R. Jones, F. Giles, B. S. Andersson, R. Champlin, and M. de Lima Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure Blood, August 15, 2006; 108(4): 1421 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. von Bubnoff, P. W. Manley, J. Mestan, J. Sanger, C. Peschel, and J. Duyster Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107) Blood, August 15, 2006; 108(4): 1328 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mourali, A. Benard, F. C. Lourenco, C. Monnet, C. Greenland, C. Moog-Lutz, C. Racaud-Sultan, D. Gonzalez-Dunia, M. Vigny, P. Mehlen, et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol. Cell. Biol., August 1, 2006; 26(16): 6209 - 6222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ye, N. Wolff, L. Li, S. Zhang, and R. L. Ilaria Jr STAT5 signaling is required for the efficient induction and maintenance of CML in mice Blood, June 15, 2006; 107(12): 4917 - 4925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Tokarski, J. A. Newitt, C. Y. J. Chang, J. D. Cheng, M. Wittekind, S. E. Kiefer, K. Kish, F. Y.F. Lee, R. Borzillerri, L. J. Lombardo, et al. The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants Cancer Res., June 1, 2006; 66(11): 5790 - 5797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ault, H. Kantarjian, S. O'Brien, S. Faderl, M. Beran, M. B. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, et al. Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib J. Clin. Oncol., March 1, 2006; 24(7): 1204 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Martinelli, I. Iacobucci, G. Rosti, F. Pane, M. Amabile, F. Castagnetti, D. Cilloni, S. Soverini, N. Testoni, G. Specchia, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients Ann. Onc., March 1, 2006; 17(3): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Mauro and R. T. Maziarz Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia: When Should It Be Used? Mayo Clin. Proc., March 1, 2006; 81(3): 404 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aloisi, S. Di Gregorio, F. Stagno, P. Guglielmo, F. Mannino, M. P. Sormani, P. Bruzzi, C. Gambacorti-Passerini, G. Saglio, S. Venuta, et al. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B Blood, February 15, 2006; 107(4): 1591 - 1598. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Iacobucci, G. Rosti, M. Amabile, A. Poerio, S. Soverini, D. Cilloni, N. Testoni, E. Abruzzese, E. Montefusco, E. Ottaviani, et al. Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment J. Clin. Oncol., January 20, 2006; 24(3): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich Sr, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon II, et al. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme J. Clin. Oncol., December 20, 2005; 23(36): 9359 - 9368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hess, D. Bunjes, W. Siegert, R. Schwerdtfeger, G. Ledderose, B. Wassmann, G. Kobbe, M. Bornhauser, A. Hochhaus, A. J. Ullmann, et al. Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study J. Clin. Oncol., October 20, 2005; 23(30): 7583 - 7593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dresemann Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series Ann. Onc., October 1, 2005; 16(10): 1702 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, D. K. Walters, E. P. Stoffregen, D. W. Sherbenou, M. C. Heinrich, M. W.N. Deininger, and B. J. Druker Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib Clin. Cancer Res., October 1, 2005; 11(19): 6987 - 6993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Willis, T. Lange, S. Demehri, S. Otto, L. Crossman, D. Niederwieser, E. P. Stoffregen, S. McWeeney, I. Kovacs, B. Park, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood, September 15, 2005; 106(6): 2128 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Talpaz, A. Rakhit, K. Rittweger, S. O'Brien, J. Cortes, S. Fettner, L. Hooftman, and H. Kantarjian Phase I Evaluation of a 40-kDa Branched-Chain Long-Acting Pegylated IFN-{alpha}-2a With and Without Cytarabine in Patients with Chronic Myelogenous Leukemia Clin. Cancer Res., September 1, 2005; 11(17): 6247 - 6255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sorel, F. Chazelas, A. Brizard, and J.-C. Chomel Double-Gradient-Denaturing-Gradient Gel Electrophoresis for Mutation Screening of the BCR-ABL Tyrosine Kinase Domain in Chronic Myeloid Leukemia Patients Clin. Chem., July 1, 2005; 51(7): 1263 - 1266. [Full Text] [PDF]
|
|
|
|
|
|
M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P. W. Manley, J. Mestan, M. Dugan, L. Alland, J. D. Griffin, et al. AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia Clin. Cancer Res., July 1, 2005; 11(13): 4941 - 4947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Soverini, G. Martinelli, G. Rosti, S. Bassi, M. Amabile, A. Poerio, B. Giannini, E. Trabacchi, F. Castagnetti, N. Testoni, et al. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia J. Clin. Oncol., June 20, 2005; 23(18): 4100 - 4109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. J. Issa, V. Gharibyan, J. Cortes, J. Jelinek, G. Morris, S. Verstovsek, M. Talpaz, G. Garcia-Manero, and H. M. Kantarjian Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate J. Clin. Oncol., June 10, 2005; 23(17): 3948 - 3956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, D. K. Walters, E. P. Stoffregen, T. Jia, P. W. Manley, J. Mestan, S. W. Cowan-Jacob, F. Y. Lee, M. C. Heinrich, M. W.N. Deininger, et al. In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants Cancer Res., June 1, 2005; 65(11): 4500 - 4505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia Blood, May 15, 2005; 105(10): 3995 - 4003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-H. Tseng, H.-P. Lin, J. Zhu, K.-F. Chen, E. M. Hade, D. C. Young, J. C. Byrd, M. Grever, K. Johnson, B. J. Druker, et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance Blood, May 15, 2005; 105(10): 4021 - 4027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia Blood, March 15, 2005; 105(6): 2281 - 2286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Appel, A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, and P. Brossart Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-{kappa}B and Akt Signaling Pathways Clin. Cancer Res., March 1, 2005; 11(5): 1928 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chu, H. Xu, N. P. Shah, D. S. Snyder, S. J. Forman, C. L. Sawyers, and R. Bhatia Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment Blood, March 1, 2005; 105(5): 2093 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Koon, G. J. Bubley, L. Pantanowitz, D. Masiello, B. Smith, K. Crosby, J. Proper, W. Weeden, T. E. Miller, P. Chatis, et al. Imatinib-Induced Regression of AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., February 10, 2005; 23(5): 982 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Cohen, J. R. Johnson, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summary: Conversion of Imatinib Mesylate (STI571; Gleevec) Tablets from Accelerated Approval to Full Approval Clin. Cancer Res., January 1, 2005; 11(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yin, Y.-L. Wu, H.-P. Sun, G.-L. Sun, Y.-Z. Du, K.-K. Wang, J. Zhang, G.-Q. Chen, S.-J. Chen, and Z. Chen Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein Blood, December 15, 2004; 104(13): 4219 - 4225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baccarani, G. Martinelli, G. Rosti, E. Trabacchi, N. Testoni, S. Bassi, M. Amabile, S. Soverini, F. Castagnetti, D. Cilloni, et al. Imatinib and pegylated human recombinant interferon-{alpha}2b in early chronic-phase chronic myeloid leukemia Blood, December 15, 2004; 104(13): 4245 - 4251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia Blood, December 1, 2004; 104(12): 3507 - 3512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Champagne, R. Capdeville, M. Krailo, W. Qu, B. Peng, M. Rosamilia, M. Therrien, U. Zoellner, S. M. Blaney, and M. Bernstein Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study Blood, November 1, 2004; 104(9): 2655 - 2660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Branford, Z. Rudzki, I. Parkinson, A. Grigg, K. Taylor, J. F. Seymour, S. Durrant, P. Browett, A. P. Schwarer, C. Arthur, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood, November 1, 2004; 104(9): 2926 - 2932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O'Hare, R. Pollock, E. P. Stoffregen, J. A. Keats, O. M. Abdullah, E. M. Moseson, V. M. Rivera, H. Tang, C. A. Metcalf III, R. S. Bohacek, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML Blood, October 15, 2004; 104(8): 2532 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, R. Luthra, F. Giles, S. Verstovsek, S. Faderl, D. Thomas, G. Garcia-Manero, M. B. Rios, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} Blood, October 1, 2004; 104(7): 1979 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Baker, J. G. Gurney, K. K. Ness, R. Bhatia, S. J. Forman, L. Francisco, P. B. McGlave, L. L. Robison, D. S. Snyder, D. J. Weisdorf, et al. Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study Blood, September 15, 2004; 104(6): 1898 - 1906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Smith, J. M. Bullock, B. M. Booker, C. E. Haas, C. S. Berenson, and W. J. Jusko Induction of imatinib metabolism by hypericum perforatum Blood, August 15, 2004; 104(4): 1229 - 1230. [Full Text] [PDF]
|
|
|
|
|
|
J. A.E. Irving, S. O'Brien, A. L. Lennard, L. Minto, F. Lin, and A. G. Hall Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib Clin. Chem., July 1, 2004; 50(7): 1233 - 1237. [Full Text] [PDF]
|
|
|
|
|
|
S. Soverini, G. Martinelli, M. Amabile, A. Poerio, M. Bianchini, G. Rosti, F. Pane, G. Saglio, and M. Baccarani Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib Clin. Chem., July 1, 2004; 50(7): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood, June 15, 2004; 103(12): 4396 - 4407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development Clin. Cancer Res., June 1, 2004; 10(11): 3885 - 3896. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Guilhot Indications for Imatinib Mesylate Therapy and Clinical Management Oncologist, June 1, 2004; 9(3): 271 - 281. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
), and disease control can be maintained in some patients by
increasing the dosages of previously effective drugs.
and c-Kit, but does not affect other members of the type
III receptor kinase family, such as Flt-3 and Fms.
2 or
log-rank tests were used to identify prognostic factors at a
significance level of P < .2. Factors meeting this
criterion were included as terms in logistic regression or multivariate Cox models. Factors with no significant effect at a level of
P < .10 in multivariate analysis were removed, whereas
factors remaining in the multivariate model were interpreted as
independently predictive of the corresponding efficacy outcome.
